Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

The UK STOIC RCT (n=146) found early administration of inhaled budesonide reduced likelihood of urgent medical care after early COVID-19 (event rate in ITT population 3% vs 15%; p=0·009; NNT=8) and clinical recovery (median 7 vs 8 days; p=0·007) vs placebo.

Source:

The Lancet Respiratory Medicine